A statistical method, Matching-Adjusted Indirect Comparison (MAIC), has been used to evaluate the effectiveness of different PARP inhibitor combinations for treating metastatic castration-resistant prostate cancer (mCRPC).
The study, published on Nature, found that a combination of talazoparib and enzalutamide (TALA + ENZA) may be more effective than other PARP inhibitor combinations, such as olaparib plus abiraterone acetate and niraparib plus abiraterone acetate. TALA + ENZA was found to slow cancer progression, particularly in patients with homologous recombination repair mutations.
The combination also showed a better PSA response compared to olaparib plus abiraterone acetate. However, the article acknowledges the limitations of indirect comparisons and emphasizes the need for further research.
If they have banned me they must have had a good reason, which of course they did not have the guts to explain publicly (as they have deleted my post where I was simply stating that i would have contributed my articles here and not on APC and telling my friends that yhey could always find me here). They limited themselves to define me as someone who built a little credibility on their community and then wanted to exploit it for personal gains.
And I was asked few months ago, by the same person who banned me, to contribute (for free of course) to a new project with my articles. How ironic. As I stated when health unlocked contacted me after I was banned, my website is just a repository, not a community, so there was no direct competition with APC...but still...
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.